Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

Haematologica

Volumn 97, Issue 4, 2012, Pages 616-621

  Rosiñol, Laura ^a   García Sanz, Ramón ^b   Lahuerta, Juan José ^c   Hernández García, Miguel ^d   Granell, Miquel ^e   de la Rubia, Javier ^f   Oriol, Albert ^g   Hernández Ruiz, Belén ^h   Rayón, Consuelo ⁱ   Navarro, Isabel ^j   García Ruiz, Juan Carlos ^k   Besalduch, Joan ^l   Gardella, Santiago ^m   Jiménez, Javier López ⁿ   Díaz Mediavilla, Joaquín ^o   Alegre, Adrián ^p   San Miguel, Jesús ^b   Bladé, Joan ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^e Hospital Sant Pau   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h Hospital Nuestra Señora de Alarcos   (Spain)

ⁱ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^j HOSPITAL DE SAGUNTO   (Spain)

^k HOSPITAL DE CRUCES   (Spain)

^l HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^m Hospital Josep Trueta   (Spain)

ⁿ HOSPITAL RAMÓN Y CAJAL   (Spain)

^o HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^p HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

more..

Author keywords

Multiple myeloma; Outcome; Primary refractory disease; Progressive disease; Stable disease

Indexed keywords

BORTEZOMIB; BUSULFAN; CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84859464469     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.051441     Document Type: Article

References (34)

1. Attal M, Haroussau JL, Stopa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. N Engl J Med. 1996;335(3):91-97.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Phil D, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy stem-cell rescue for multiple myeloma. N Engl Med. 2003;348(19):1875-1883.
3. Pineda-Roman M, Barlogie B, Anaissie E, Zangari M, Bolejack V, Van Rhee F, et al. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer. 2008;112(8):1754-1764
4. Bladé J, Rosiñol L, Cibeira MT, Rovira M, Carreras E. Hematopietic stem cell transplantation for multiple myeloma beyond 2010. Blood. 2010;115(18):3655-3663.
5. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a populationbased study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25(15):1993-1999.
6. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521-2526.
7. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy M, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and impact of novel therapies. Blood. 2008;111(5):2516-2520.
8. Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, et al. High-dose therapy intensification com pared with continued standard chemotherapy in multiple myeloma patients responding to the inicial chemotherapy: long-term results from a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood. 2005;106(12):3755-3759.
9. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. Highdose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005; 23(36):9227-9233.
10. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. J Clin Oncol. 2006;24(6):929-936.
11. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495-2502.
12. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous transplatation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434-2441.
13. Bladé J, Vesole DH, Gertz M. Trans - plantation for multiple myeloma: who, when, how often? Blood. 2003;102(10): 3469-3477.
14. Dimopoulos MA, Hester J, Huh Y, Champlin R, Alexanian R. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol. 1994;87(4):730-734.
15. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood. 1994:84(12);4278-4282.
16. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood. 1994;84(3):950-956.
17. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 1999;23(12):1267-1272.
18. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Metha J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 2002;30(10):673-679.
19. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004;34(2):161-167.
20. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant. 2004;34(3):229-234.
21. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos D, Kyle RA, et al. Consensus recommendations for the uniform reporting of clinical trials. Report of the International Myeloma Workshop Consensus Panel I. Blood. 2011;117(18): 4691-4695.
22. Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112 (9):3591-3593.
23. Chronic Leukemia-Myeloma Task Force. National Cancer Institute. Porposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep. 1973;4: 145-158.
24. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115-1123.
25. Peto R, Pike MC. Conservation of the approximation sigma (O-E)2-E in the log rank test for survival data or tumor incidence data. Biometrics. 1973;29(3):579-584.
26. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27(10):1037-1043.
27. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant. 2010;45(3):498-504.
28. Nadal E, Giné E, Bladé J, Esteve J, Rosiñol L, Fernández Avilés, et al. High-dose therapy/ autologus stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant. 2004;33(1): 61-64.
29. Bladé J, San Miguel JF, Fontanillas M, Esteve J, Maldonado J, Alcalá J, et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J. 2001; 2(4):272-278.
30. Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, et al. Influence of pre- and postransplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775-5782.
31. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollnig K, Pineda-Román M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Hematol. 2007;138(2):176-185.
32. Cavo M, Tachetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before and consolidation therapy after double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet. 2010;376 (9758):2075-2085.
33. Popat R, Oakervee HE, Hallan S, Curry N, Odeh L, Foot N, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma updated results after long-term follow-up. Br J Haematol. 2008;141(4):512-516.
34. Rosiñol L, Cibeira MT, Mateos MV, Martínez J, Oriol A, Teruel A, et al. A phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: Superiority of VTD (bortezomib/thalidomide/ dexamethasone) over TD and VBMCP/VBAD plus Bortezomib. Blood. 2010;116(21):139 (abstract 307).